Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non–ST-Elevation Acute Coronary Syndromes

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Lincoff, A.Michael
Califf, Robert M
Topol, Eric J

April 2000

AbstractNew strategies for profound inhibition of platelet activity at the injured coronary plaque f...

Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients

KS Rathod
S Antoniou
P Avari
N Ding
P Wright
C Knight
AK Jain
A Mathur
EJ Smith
R Weerackody
A Wragg
DA Jones

October 2017

Introduction Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in patients with ST-segm...

Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention

김진현
신상진
김은주
이영희

January 2007

This study was performed to analyse the economic value of abciximab which is used in PCI to prevent ...

Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis

Latour-Pérez, Jaime
de Miguel Balsa, Eva
Betegón, Lourdes
Badia, Xavier

October 2008

AbstractObjectivesTo assess the incremental cost-effectiveness ratio (ICER) of glycoprotein IIb/IIIa...

Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

Palmer, S.
Sculpher, M.
Philips, Z.
Robinson, M.
Ginnelly, L.
Bakhai, A.
Abrams, K.
Cooper, N.
Packham, C.
Alfakih, K.
Hall, A.
Gray, D.

April 2005

BAACKGROUND The glycoprotein IIb/IIIa antagonists (GPAs) represent a new class of drugs to preven...

Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin

Keaven M. Anderson
Linda Davidson-ray
J. David Knight
Catherine F. Cabot
Eric J
A. Michael Lincoff
Daniel B. Mark
James E. Tcheng
Robert M. Califf
Mohan V. Bala
Mohan V. Bala
Phd Keaven
M. Anderson
Phd Linda Davidson-ray
Ba J. David Knight
Catherine F. Cabot
Md Eric
J. Topol
Md For The Epilog Investigators

December 2014

The online version of this article, along with updated information and services, is located on th

Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome

M Momtahen
S Abdi
F Javadzadeh
Bf Farsad
As Kazzazi
S Momtahen
M Momtahen

October 2016

glycoprotein IIb/IIIa receptor3-5 which is final common pathway of platelet aggregation. It is recom...

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel or both?

Matthew A Silva
Jennifer L Donovan
Pritesh J Gandhi
Gregory A Volturo

March 2006

Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College...

Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status

Eric J. Topol
Harvey D. White
Paul W. Armstrong
Frans Van De Werf
Matthias Pfisterer
Vic Hasselblad
Robert M
L. Kristin Newby
E. Magnus Ohman
Robert H. Christenson
David J. Moliterno
Robert A. Harrington
The Paragon-b
Troponin T Substudy
Eric J. Topol
Md For The Paragon-b Investigators

December 2014

The online version of this article, along with updated information and services, is located on the W...

Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in

Eric J. Topol
Robert M. Califf
Robert A. Harrington
Lisa G. Berdan
Todd J. Lorenz
Dennis V. Cokkinos
Maarten L. Simoons
Neal S. Kleiman
A. Michael Lincoff
Greg C. Flaker
Karen S. Pieper
R. G. Wilcox
Robert A. Harrington
Md For The Pursuit Investigators

August 2016

located on the World Wide Web at: The online version of this article, along with updated information...

EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME

A. V. Rudakova
N. V. Lomakin

September 2015

<p>Dual antiplatelet therapy, including clopidogrel and aspirin, in a significant share of patients ...

Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial.

Brown, R.E.
Henderson, R.A.
Koster, D.
Hutton, J.
Simoons, M.L.

January 2002

AIMS To assess the direct medical costs and cost effectiveness of routine eptifibatide use amongs...

Platelet Glycoprotein IIb/IIIa Inhibitors Basic and Clinical Aspects

Alan T. Nurden
Christel Poujol
Catherine Durrieu-jais
Paquita Nurden
Arterioscler Thromb Vasc Biol
Alan T. Nurden
Christel Poujol
Catherine Durrieu-jais
Paquita Nurden

December 2014

The online version of this article, along with updated information and services, is located on th

Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex

Eric J. Topol
Khaled M. Ziada
Katherine E. Wolski
David J. Moliterno
Sorin J. Brener
Stephen G. Ellis
O A. Cura
Deepak L. Bhatt
A. Michael Lincoff
Samir R. Kapadia
Atherosclerotic Lesions

August 2015

The online version of this article, along with updated information and services, is located on th

Cost-effectiveness of preference-based antithrombotic therapy for patients with non-valvular atrial fibrillation

Brian F. Gage
Andria B. Cardinalli
Douglas K. Owens
Nonvalvular Atrial Fibrillation

January 1998

The online version of this article, along with updated information and services, is located on th

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Lincoff, A.Michael
Califf, Robert M
Topol, Eric J

April 2000

AbstractNew strategies for profound inhibition of platelet activity at the injured coronary plaque f...

Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients

KS Rathod
S Antoniou
P Avari
N Ding
P Wright
C Knight
AK Jain
A Mathur
EJ Smith
R Weerackody
A Wragg
DA Jones

October 2017

Introduction Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in patients with ST-segm...

Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention

김진현
신상진
김은주
이영희

January 2007

This study was performed to analyse the economic value of abciximab which is used in PCI to prevent ...

Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis

Latour-Pérez, Jaime
de Miguel Balsa, Eva
Betegón, Lourdes
Badia, Xavier

October 2008

AbstractObjectivesTo assess the incremental cost-effectiveness ratio (ICER) of glycoprotein IIb/IIIa...

Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

Palmer, S.
Sculpher, M.
Philips, Z.
Robinson, M.
Ginnelly, L.
Bakhai, A.
Abrams, K.
Cooper, N.
Packham, C.
Alfakih, K.
Hall, A.
Gray, D.

April 2005

BAACKGROUND The glycoprotein IIb/IIIa antagonists (GPAs) represent a new class of drugs to preven...

Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin

Keaven M. Anderson
Linda Davidson-ray
J. David Knight
Catherine F. Cabot
Eric J
A. Michael Lincoff
Daniel B. Mark
James E. Tcheng
Robert M. Califf
Mohan V. Bala
Mohan V. Bala
Phd Keaven
M. Anderson
Phd Linda Davidson-ray
Ba J. David Knight
Catherine F. Cabot
Md Eric
J. Topol
Md For The Epilog Investigators

December 2014

The online version of this article, along with updated information and services, is located on th

Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome

M Momtahen
S Abdi
F Javadzadeh
Bf Farsad
As Kazzazi
S Momtahen
M Momtahen

October 2016

glycoprotein IIb/IIIa receptor3-5 which is final common pathway of platelet aggregation. It is recom...

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel or both?

Matthew A Silva
Jennifer L Donovan
Pritesh J Gandhi
Gregory A Volturo

March 2006

Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College...

Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status

Eric J. Topol
Harvey D. White
Paul W. Armstrong
Frans Van De Werf
Matthias Pfisterer
Vic Hasselblad
Robert M
L. Kristin Newby
E. Magnus Ohman
Robert H. Christenson
David J. Moliterno
Robert A. Harrington
The Paragon-b
Troponin T Substudy
Eric J. Topol
Md For The Paragon-b Investigators

December 2014

The online version of this article, along with updated information and services, is located on the W...

Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in

Eric J. Topol
Robert M. Califf
Robert A. Harrington
Lisa G. Berdan
Todd J. Lorenz
Dennis V. Cokkinos
Maarten L. Simoons
Neal S. Kleiman
A. Michael Lincoff
Greg C. Flaker
Karen S. Pieper
R. G. Wilcox
Robert A. Harrington
Md For The Pursuit Investigators

August 2016

located on the World Wide Web at: The online version of this article, along with updated information...

EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME

A. V. Rudakova
N. V. Lomakin

September 2015

<p>Dual antiplatelet therapy, including clopidogrel and aspirin, in a significant share of patients ...

Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial.

Brown, R.E.
Henderson, R.A.
Koster, D.
Hutton, J.
Simoons, M.L.

January 2002

AIMS To assess the direct medical costs and cost effectiveness of routine eptifibatide use amongs...

Platelet Glycoprotein IIb/IIIa Inhibitors Basic and Clinical Aspects

Alan T. Nurden
Christel Poujol
Catherine Durrieu-jais
Paquita Nurden
Arterioscler Thromb Vasc Biol
Alan T. Nurden
Christel Poujol
Catherine Durrieu-jais
Paquita Nurden

December 2014

The online version of this article, along with updated information and services, is located on th

Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex

Eric J. Topol
Khaled M. Ziada
Katherine E. Wolski
David J. Moliterno
Sorin J. Brener
Stephen G. Ellis
O A. Cura
Deepak L. Bhatt
A. Michael Lincoff
Samir R. Kapadia
Atherosclerotic Lesions

August 2015

The online version of this article, along with updated information and services, is located on th

Cost-effectiveness of preference-based antithrombotic therapy for patients with non-valvular atrial fibrillation

Brian F. Gage
Andria B. Cardinalli
Douglas K. Owens
Nonvalvular Atrial Fibrillation

January 1998

The online version of this article, along with updated information and services, is located on th

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Lincoff, A.Michael
Califf, Robert M
Topol, Eric J

April 2000

AbstractNew strategies for profound inhibition of platelet activity at the injured coronary plaque f...

Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients

KS Rathod
S Antoniou
P Avari
N Ding
P Wright
C Knight
AK Jain
A Mathur
EJ Smith
R Weerackody
A Wragg
DA Jones

October 2017

Introduction Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in patients with ST-segm...

Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention

김진현
신상진
김은주
이영희

January 2007

This study was performed to analyse the economic value of abciximab which is used in PCI to prevent ...

Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non–ST-Elevation Acute Coronary Syndromes

Abstract

Extracted data

Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non–ST-Elevation Acute Coronary Syndromes

Abstract

Extracted data

Related items

Related items